(IN BRIEF) Thousands of men with early-stage prostate cancer in England will now be offered stereotactic body radiotherapy, also known as stereotactic ablative radiotherapy, through the NHS after results from the PACE-B trial showed the treatment can be as effective … Read the full press release
Posted in Education, Government, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cancer care, cancer recurrence, cancer treatment, clinical research, Clinical Trials and Statistics Unit, early-stage prostate cancer, England, five-session treatment, gastrointestinal side effects, genital and urinary side effects, high-powered radiotherapy, hospital appointments, ICR, ICR and Royal Marsden Trial Supports Faster Radiotherapy Option for Prostate Cancer Patients, IMRT, intensity-modulated radiotherapy, localised prostate cancer, low-risk prostate cancer, medium-risk prostate cancer, NHS England, NHS England Approves SBRT for Eligible Men with Low and Medium-Risk Prostate Cancer, NHS radiotherapy centres, PACE-B trial, Phase III Trial, precision radiotherapy, Professor Emma Hall, Professor Nicholas van As, Professor Peter Johnson, prostate cancer, radiation beams, radiotherapy, randomised trial, SABR, SBRT, Shorter High-Powered Radiotherapy Course Set to Reduce Treatment Burden for Prostate Cancer Patients, stereotactic ablative radiotherapy, stereotactic body radiotherapy, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Thousands of Men in England to Benefit from More Precise Five-Visit Prostate Cancer Radiotherapy, treatment side effects, tumour targeting, United Kingdom
(IN BRIEF) Scientists at The Institute of Cancer Research, London, and the University of Oxford have uncovered a mechanism that helps cancer cells survive radiotherapy by repairing radiation-induced DNA damage. The study found that insulin-like growth factor 1 receptor, or … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Balmus Laboratory, Blocking Cancer Cell Repair Pathway May Strengthen Future Radiotherapy Strategies, Cancer and Genome Instability Group, cancer cell survival, cancer research, Cancer Research UK, cancer therapy, cell survival mechanisms, chromatin, combination treatments, DNA damage response, DNA repair, DNA-dependent protein kinase catalytic subunit, DNA-PKcs, double-strand breaks, Dr Matthew Ellis, Dr Valentine Macaulay, drug targets, end-joining, genome instability, growth signalling, ICR, IGF-1R, insulin-like growth factor 1 receptor, Medical Research Council, Molecular Oncology, New Study Links Cancer Growth Receptor to DNA Repair After Radiation Treatment, non-homologous end joining, oncology, precision treatment, Professor Wojciech Niedzwiedz, prostate cancer, Prostate Cancer UK, radiation treatment, radiotherapy, Research Reveals How IGF-1R Helps Tumours Survive Radiation-Induced DNA Damage, resistant tumours, Targeting IGF-1R Could Make Cancer Cells More Vulnerable to Radiotherapy, The Institute of Cancer Research, treatment resistance, tumour biology, United Kingdom, University of Cambridge, University of Oxford
(IN BRIEF) Researchers from the Luxembourg Institute of Health’s NORLUX Neuro-Oncology Laboratory have contributed to an international study published in Nature that sheds new light on how adult brain tumours, particularly IDH-mutant gliomas, evolve and become more aggressive after treatment. … Read the full press release
Posted in Artificial Intelligence (AI), Education, European Union, Healthcare, Luxembourg, Pharma & Biotech, Science, Technology
Tagged adult brain tumours, brain cancer, brain tumours, C20/BM/14646004/GLASSLUX, cancer cells, cancer research, chemotherapy, Department of Cancer Research, Dr Anna Golebiewska, FNR, genomic technologies, GLASSLUX, glioma recurrence, IDH inhibitors, IDH-mutant gliomas, immature cancer cells, INTER/TRANSCAN22/17612718/PLASTIG, international research consortium, LIH, LIH NORLUX Lab Contributes to Nature Study Advancing Understanding of Brain Tumour Evolution and Recurrence, LIH NORLUX Lab Contributes to Nature Study Revealing How Brain Tumours Become More Aggressive Over Time, longitudinal tumour samples, Luxembourg Institute of Health, Luxembourg National Research Fund, nature, Nature Study with LIH NORLUX Contribution Identifies Biological Pathways Driving Brain Tumour Progression, neuro-oncology, NORLUX Lab Contributes Rare Patient Samples and Preclinical Models to Major Study on Glioma Recurrence, NORLUX Neuro-Oncology Laboratory, patient-derived preclinical models, personalised treatment, PLASTIG, PRECISION-PDX cohort, radiotherapy, single-cell technologies, therapy resistance, tumour environment, tumour evolution, tumour progression
(IN BRIEF) The University of Warwick-coordinated OPTIMA trial, sponsored by University College London, has found that the Prosigna genomic test could help many patients with early-stage hormone-sensitive breast cancer avoid unnecessary chemotherapy without compromising outcomes. The trial followed more than … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged Adrienne Morgan, American Society of Clinical Oncology, ASCO Annual Meeting, breast cancer, breast oncology, cancer recurrence, cancer research, Cardiff, chemotherapy, clinical trial, early stage breast cancer, gene test, genomic test, hormone therapy, hormone-sensitive breast cancer, Independent Cancer Patients’ Voice, Karen Bonham, lymph nodes, Major OPTIMA Trial Results Could Support Wider NHS Use of Genomic Testing to Reduce Chemotherapy Overtreatment, National Institute for Health and Care Research, NHS, NHS laboratories, Nice, NIHR, OPTIMA trial, Patient and Public Involvement, patient outcomes, personalised treatment, Professor Janet Dunn, Professor Rob Stein, Prosigna, radiotherapy, treatment decision-making, tumour biology, UCL, UCL Cancer Institute, University College London, University of Warwick, University of Warwick and UCL-Led Breast Cancer Trial Highlights Potential to Spare Thousands from Chemotherapy, University of Warwick-Coordinated OPTIMA Trial Shows Genomic Test Could Help Breast Cancer Patients Avoid Unnecessary Chemotherapy, unnecessary chemotherapy, Veracyte Inc, Warwick Clinical Trials Unit
(IN BRIEF) Synaptiq is streamlining radiotherapy preparation with its AI‑driven contouring software, which automates the delineation of tumours and organs at risk. Founded by Dragoș Dușe and Roxana Săbău, the Romanian startup emerged from research at Germany’s Cancer Research Centre and now … Read the full press release
Posted in Artificial Intelligence (AI), Banks, Business, Economy, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Romania, Technology, United Kingdom
Tagged AI contouring, cancer care innovation, cancer research, clinical expansion, CT, Dragoș Dușe, EBRD, healthtech, Heidelberg, MRI, organs at risk, partnership, patent, prompt‑based AI, radiotherapy, Romania, Roxana Săbău, Star Venture programme, Synaptiq, TaiwanBusiness-EBRD Technical Cooperation Fund, tumour delineation
(IN BRIEF) PATRIZIA has finalised an 81,000 sq ft pre‑let to Cleveland Clinic London at 40 Grosvenor Place for a new cancer centre opening in 2027. The centre will span seven floors and feature advanced treatment capabilities—systemic therapies, radiotherapy and outpatient care. PATRIZIA’s … Read the full press release
Posted in Business, Environment, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, News, Real Estate, Science, Technology, United Kingdom
Tagged 40 Grosvenor Place, asset repositioning, cancer treatment centre, CBRE, central London real estate, Christie Wright, Cleveland Clinic London, clinical space, Knight Frank, outpatient care, partnership, PATRIZIA, pre‑let, radiotherapy, systemic therapies
(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss radionuclide theranostics’ role in transforming precision oncology. The event featured expert presentations on advancements in radiopharmaceuticals, clinical development challenges, and … Read the full press release
Posted in Berlin, Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Technology
Tagged Boston Radionuclide Theranostics Forum, clinical development, Dr. Harald Hasselmann, Eckert & Ziegler, German American Business Council, Industry innovation, Morrison Foerster, nuclear medicine, patient access, precision oncology, radionuclide theranostics, radiopharmaceutical community, radiopharmaceuticals, radiotherapy, Solomon Partners
(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Acute myeloid leukemia, cancer treatment, clinical trials, CXCR4, Dirk Pleimes, Eckert & Ziegler, EZR, Ga68-PentixaFor, GMP manufacturing, Harald Hasselmann, lymphoma, Myeloma, nuclear medicine, Pentixapharm, radiopharmaceuticals, radiotherapy, solid tumors, targeted therapy, theranostics, Y90-PentixaTher
(PRESS RELEASE) BRISTOL, 19-Apr-2022 — /EuropaWire/ — University of Bristol, a red brick research university, has announced that it led a new research on the link between body mass index (BMI) and endometrial cancer risk. The study, funded by Cancer … Read the full press release
Posted in Education, Healthcare, News, Science, Society, Technology, United Kingdom
Tagged BMC Medicine, BMI, cancer free, cancer research, chemotherapy, Dr Julie Sharp, Emma Hazelwood, endometrial cancer, excess weight, gynaecological cancer, menopause, Obesity, radiotherapy, RESEARCH, University of Bristol, womb cancer
EQT Infrastructure has agreed to acquire Icon Group from a consortium including Goldman Sachs Asset Management, QIC and Pagoda. Goldman Sachs Asset Management will remain a minority shareholder as part of the transaction Icon Group is Australia’s largest vertically integrated cancer … Read the full press release
Posted in Business, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Sweden, Technology
Tagged acquisition, Australia, Blikk, cancer care, cancer clinical trials, cancer drug infusions, cancer patients, cancer treatment, compounding, decentralisation, Deloitte, diagnostic imaging provider, digitalization, EQT, EQT Infrastructure, EQT Infrastructure V, Goldman Sachs Asset Management, healthcare sector, Herbert Smith Freehills, I-MED, Icon Group, integrated cancer-care operator, Integrated Clinical Oncology Network, investment, Jim Kelly, Ken Wong, Mark Middleton, medical oncology, Meine Radiologie Holding, Morgan Stanley, nuclear medicine, oncology, Pagoda Investment Advisors, pharmacy, PwC, QIC Private Capital Pty Ltd, Radiation Oncology, radiology, radiotherapy, Stephanie Hui
Palette Life Sciences provides valuable information regarding vesicoureteral reflux (VUR) to paediatric urologists in France, Germany, Italy and Spain (PRESS RELEASE) SANTA BARBARA, CALIF. / STOCKHOLM, 27-Oct-2020 — /EuropaWire/ — Palette Life Sciences, a fully integrated global life sciences company … Read the full press release
Posted in Education, France, Germany, Healthcare, Internet & Online, Italy, News, Pharma & Biotech, Spain, Sweden
Tagged Barrigel®, CE-Mark, Chelsea & Westminster, colorectal conditions, Deflux, Deflux Learning Center, Deflux®, dextranomer, Dr. Marie-Klaire Farrugia, Dx, educational resources, healthcare community, healthcare providers, Imperial College Hospitals, interventional oncology, Lidbree ™, life sciences, medical solutions, microspheres, NASHA®, online resources, online resources for healthcare providers, pae, paediatric, paediatric urinary condition, Palette Life Sciences, physicians, polysaccharides, Q-Med, radiotherapy, Rich Low, Solesta®, urine reflux, urogynaecology disorders, urology, UTI, vesicoureteral reflux, VUR
(PRESS RELEASE) SANTA BARBARA, CALIF., U.S.A. / BUDAPEST / STOCKHOLM, 5-Aug-2020 — /EuropaWire/ — Palette Life Sciences AB (‘Palette’) with Gedeon Richter Plc. (‘Richter’), today announced that as a part of a decentralised regulatory procedure including thirty European Union Economic … Read the full press release
Posted in European Union, Healthcare, Hungary, Marketing, News, Pharma & Biotech, Sweden, United Kingdom
Tagged anesthetic lidocaine, Barrigel®, cervical, colorectal conditions, Deflux®, endometrial biopsies, European Union Economic Area member states, Gedeon Richter Plc., Gunvor Ekman-Ordeberg MD PhD, gynecological interventions, gynecological procedures, gynecology, Helena Jansson, hysteroscopy, interventional oncology, intrauterine contraception, Karolinska Institute, LIDBREE program, LIDBREE™, marketing, marketing authorization, Novel Pain Relief Product, pain relief, Palette Life Sciences AB, proprietary thermo gelling intrauterine, radiotherapy, Solesta®, Tibor Horváth, urogynecology disorders, urology, Zsuzsa Beke
(PRESS RELEASE) STOCKHOLM, SWEDEN / SANTA BARBARA, CALIF., USA, 15-Jun-2020 — /EuropaWire/ — Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced global distribution expansion for two of Palette’s products, Deflux and … Read the full press release
Posted in Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Healthcare, Hungary, Iceland, Ireland, Italy, Luxembourg, Malta, Marketing, Netherlands, News, Norway, Pharma & Biotech, Portugal, Retail, Spain, Sweden, Switzerland, United Kingdom
Tagged Barrigel®, bladder, bowel incontinence, CJ Medical, colorectal, colorectal conditions, Danielle Hazarian, Deflux, Deflux®, dextranomer, fecal incontinence, GP Dermal, Grifols, injectable gel bulking agent, interventional oncology, James Leech, KEBOMED, kidneys, life sciences, oncology, Palette Life Sciences, pediatric, polysaccharides, RA Distribution, radiotherapy, serious pediatric urinary condition, Solesta, Solesta®, Stratarium Sarl, ureter, urine reflux, urine refluxes, urogynecology, urology, vesicoureteral reflux, VUR
The new immunotherapy will be tested in humans as soon as possible (PRESS RELEASE) ZURICH, 8-May-2020 — /EuropaWire/ — University of Zurich researchers have announced a study that is showing how hematopoietic stem cells from a healthy donor can help … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acute leukemia, Acute myeloid leukemia, Alexander Simonis, AML, Antonia M. Müller, blood stem cells, bone marrow, Burkhard Becher, C. Matthias Wilk, Cancer, cancerous hematopoietic stem cells, CAR-T, chemotherapy, Chiara F. Magnani, Christian Münz, Dario Neri, Donal McHugh, ETH Zurich, genetic modification, hematology, Hematopoietic stem cells, immunotherapy, Jonathan D. Kiefer, Juliane Friemel, leukemia, Maries van den Broek, Markus G. Manz, Markus Manz, Nicolás Nuñez, Norman F. Russkamp, oncology, platelets, radiotherapy, red blood cells, Renier Myburgh, Surema Pfister, transplant, University Hospital Zurich, University of Zurich, white blood cells
Brussels, 15-4-2013 — /europawire.eu/ — Androulla Vassiliou, Commissioner for Education, Culture, Multilingualism and Youth, will visit the European Organization for Nuclear Research (CERN) in Geneva, Switzerland, on 15 April to meet scientists and researchers supported with funding from the EU Marie Curie Actions. Members of the team … Read the full press release
Posted in Belgium, European Union, Government, Healthcare, Pharma & Biotech, Politics, Science, Society, Switzerland
Tagged 3D imaging, 3D medical imaging, Androulla Vassiliou, cancer treatments, CERN, digital medical imaging for radiotherapy, ENTERVISION, European Organization for Nuclear Research, Geneva, Higgs particle, Marie Curie Actions, Marie Skłodowska-Curie Actions, radiotherapy, researchers, scientists, sub-atomic particles, tumours, X-ray technology
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?